Flavonoids as multi-target therapeutic agents: A systematic review of pharmacological evidence, molecular mechanisms, and clinical translation
Keywords:
Flavonoids, Polyphenols, Multi-target therapy, Pharmacology, Drug discovery, Molecular targets, Precision medicine, Natural products, Network pharmacology, PRISMAAbstract
Background: Flavonoids, the largest class of plant polyphenols, are increasingly recognized as multi-target therapeutic agents that can modulate diverse molecular pathways involved in chronic diseases. Unlike previous reviews focusing on individual flavonoid subclasses or specific diseases, this systematic review provides a comprehensive evaluation of their molecular mechanisms, pharmacokinetics, network pharmacology, and clinical applications. Methodology: We conducted a systematic review following the PRISMA 2020 guidelines. We searched electronic databases, including PubMed, Scopus, Web of Science, Embase, ScienceDirect, Cochrane Library, and Google Scholar, for studies published between January 2000 and March 2024. We assessed eligible in vitro, in vivo, and clinical studies using established risk-of-bias tools and evaluated evidence certainty using the GRADE framework. Results and Discussion: The review identified extensive preclinical evidence and an emerging body of clinical studies supporting flavonoids' therapeutic potential. These compounds modulate multiple molecular targets, including inflammatory mediators, kinase signaling pathways, transcription factors, and apoptotic regulators, across cancer, cardiovascular, metabolic, neurodegenerative, and inflammatory disorders. Clinical studies indicate modest but promising therapeutic benefits; however, poor oral bioavailability, rapid metabolism, and heterogeneity in study design and intervention protocols constrain broader clinical translation. Conclusion: Flavonoids demonstrate substantial multi-target therapeutic potential supported by robust mechanistic evidence and encouraging clinical findings. Nevertheless, well-designed, adequately powered clinical trials, standardized formulations, and advanced bioavailability-enhancing delivery systems are essential to establish their efficacy and facilitate widespread clinical application.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Jahnabi Sarmah, Dhiraj Bishya, Rosamund Jyrwa, Ikram Hussain

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
In submitting an article to Journal of Applied Pharmacognosy and Phytochemistry (JOAPP) I certify that:
- I am authorized by my co-authors to enter into these arrangements.
- I warrant, on behalf of myself and my co-authors, that:
- the article is original, has not been formally published in any other peer-reviewed journal, is not under consideration by any other journal and does not infringe any existing copyright or any other third party rights;
- I am/we are the sole author(s) of the article and have full authority to enter into this agreement and in granting rights to JOAPR are not in breach of any other obligation;
- the article contains nothing that is unlawful, libellous, or which would, if published, constitute a breach of contract or of confidence or of commitment given to secrecy;
- I/we have taken due care to ensure the integrity of the article. To my/our - and currently accepted scientific - knowledge all statements contained in it purporting to be facts are true and any formula or instruction contained in the article will not, if followed accurately, cause any injury, illness or damage to the user.
- I, and all co-authors, agree that the article, if editorially accepted for publication, shall be licensed under the Creative Commons Attribution-NonCommercial 4.0 International License
- I, and all co-authors, agree that, if the article is editorially accepted for publication in Journal of Applied Pharmaceutical Research (JOAPR) data included in the article shall be made available under the Creative Commons 1.0 Public Domain Dedication waiver, unless otherwise stated. For the avoidance of doubt it is stated that sections 1, 2, and 3 of this license agreement shall apply and prevail.



